Patients	PPV3 (rate of malignancy among cases with positive results on screening who underwent biopsy)
Inclusion criteria
Women with a personal history of breast cancer and had undergone curative-intent treatment	Sensitivity (TP/[TP + FP])
	Specificity (TN/[TN + FN])
Exclusion criteria	Number of screens needed to detect on cancer
Pregnant, lactating, or known metastatic disease	Recall rate (proportion of women with a positive screen result)
Non-human research participants	Emotional impact (e.g., anxiety, depression) of positive results (true- and false-positive findings)
Male study participants
Interventions	Exclusion criteria
Inclusion criteria	Outcomes not listed
Magnetic resonance imaging	Economic outcomes only
Mammography	Timing
CBE	Inclusion criteria
No screening	Articles published after 2000
Ultrasound	Studies of any duration
Exclusion criteria	Settings
Screening modalities that do not include MRI as a study group	Inclusion criteria
MRI for any purpose other than screening (i.e., diagnostic)	Any setting where MRI breast cancer screening is provided
Comparators	Study Design
Inclusion criteria	Inclusion criteria
MRI vs. Mammography (plus Ultrasound)	Controlled studies (RCTs, cohort studies, case–control studies)
MRI vs. no screening	Modeling/simulation studies that meet previously stated inclusion/exclusion criteria
Ipsilateral vs. contralateral detection
MRI at various intervals	Observational studies (prospective and retrospective cohort studies, case–control studies, or cross-sectional studies)
Women with a personal history of breast cancer vs. women without
	Exclusion criteria
Women with a personal history of breast cancer and a family history of breast cancer vs. no family history of breast cancer	Systematic reviews and/or meta-analyses
	Non-research studies (e.g., editorials, letters)
Outcomes	Other
Inclusion criteria	English language
Cancer detection rate (proportion of women with appositive screen result and a positive reference standard)	Peer-reviewed articles
	Exclusion criteria
Cancer detection rate for ipsilateral and contralateral breast cancer	Non-English language
PPV1 (malignancy rate among cases that test positive on screening) or false-positive rate	Abstracts only